INTRODUCTION
Obstructed hemivagina and ipsilateral renal anomaly (OHVIRA) syndrome, also known as Herlyn-Werner-Wunderlich syndrome, is a congenital anomaly in which unilateral mullerian duct anomaly is associated with ipsilateral renal anomaly, usually renal agenesis. It is an important cause of painful menstruation in young females. Diagnosis is often missed in early stages due to lack of awareness of this condition and due to concurrent normal menstrual flow in these patients. [1] Awareness of this condition can help in suggesting this condition on sonography. Magnetic resonance imaging (MRI) can provide exquisite detail of the anomaly and its extent.
CASE REPORT
A 14-year-old female patient who had recent onset of menarche presented with cyclical abdominal pain during
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DISCUSSION
OHVIRA syndrome was first described as early as 1922 and is also known as Herlyn-Werner-Wunderlich syndrome, named after the authors who described this entity in 1970s. [2] This condition results due to anomalous development of mullerian and mesonephric ducts during embryonic development. During early life, paired mullerian and mesonephric ducts develop from common dorsal ridge. Failure of fusion of mullerian ducts results in varying degree of anomalies ranging from uterus didelphys to septate uterus. Because of close proximity, anomalies of mullerian duct are frequently associated with ipsilateral mesonephric duct anomalies and vice versa. Mesonephric duct is responsible for the development of renal collecting system, renal pelvis, and ureter and also induces the development of renal parenchymal tissue. Its abnormal development can cause a variety of anomalies; renal agenesis being the most commonly associated renal anomaly with OHVIRA syndrome. [2] [3] [4] [5] This condition is usually diagnosed around the age of menarche when patient presents with cyclic pain during menstruation along with normal menstrual flow. [2] There are also reports of seven cases of early diagnosis of this condition, before the onset of menarche, under the age of 5 years. This suggests that all the cases of unilateral renal agenesis should be screened for mullerian anomalies. Awareness of this condition and high index of suspicion is required for early diagnosis as failure to recognize this condition can result in inadvertent resection of the pelvic cystic lesion with uncertain eventual reproductive outcome. [6] Sonography is often the first imaging modality in cases of pelvic pain. Correlation with clinical history of normal menses and hematocolpos should suggest this diagnosis, especially if there is associated renal agenesis. MRI can provide exact detail of the associated anomalies and associated endometriosis, if present. [3] The preferred treatment of OHVIRA syndrome is directed at resection of vaginal septum and vaginoplasty which can be done as a single-or two-stage procedure. [2] Hemihysterectomy which was performed earlier is no longer preferred because the reproductive outcome is similar with the conservative endovaginal procedure. [5] CONCLUSION OHVIRA syndrome is a rare cause of cyclical abdominal pain in young females. Awareness of this condition and appropriate imaging is necessary for correct and timely diagnosis. Delayed diagnosis can lead to more accumulation of blood products and eventually hematosalpinx and endometriosis with worsening of reproductive outcome. Similarly, all patients with renal agenesis should be screened for mullerian anomalies and any pelvic "cystic mass" in these patients should not be resected without further imaging.
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